Literature DB >> 6628521

The influence of uremia on the accessibility of phosphomycin into interstitial tissue fluid.

C Fernandez Lastra, E L Mariño, A Dominguez-Gil, J M Tabernero, A Gonzalez Lopez, M Yuste Chaves.   

Abstract

The entry and persistence of phosphomycin in interstitial tissue fluid (ITF) were studied in 9 patients with normal renal function and 8 patients with varying degrees of renal impairment, all of whom received a single i.v. dose of 30 mg/kg. ITF was obtained from skin blisters produced by suction. The antibiotic followed a two-compartment open kinetic model. In patients with normal renal function, phosphomycin is incorporated rapidly into the ITF reaching a level of 60.4 micrograms/ml 60 min after administration. There was no statistically significant difference between the elimination rates from serum and ITF. The serum half-life of the slow disposition phase was 1.75 h in patients with normal renal function. There was a linear correlation between the elimination half-life of phosphomycin in serum and ITF in subjects with differing degrees of renal impairment.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6628521     DOI: 10.1007/bf01037944

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  Pharmacological studies with cefamandole in human volunteers.

Authors:  B R Meyers; B Ribner; S Yancovitz; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

2.  Effect of renal failure and dialysis on the serum concentration of the aminoglycoside amikacin.

Authors:  T Madhavan; K Yaremchuk; N Levin; D Pohlod; K Burch; E Fisher; F Cox; E L Quinn
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

3.  Pharmacodynamics of phosphonomycin after intravenous administration in man.

Authors:  E L Foltz; H Wallick
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

4.  Clinical pharmacology and in vitro activity of phosphonomycin.

Authors:  D G Kestle; W M Kirby
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

5.  Pharmacokinetic study of fosfomycin and its bioavailability.

Authors:  R Cadórniga; M Diaz Fierros; T Olay
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

6.  Use of a programmable hand-held calculator for clinical pharmacokinetics.

Authors:  T S Foster; D W Bourne
Journal:  Am J Hosp Pharm       Date:  1977-01

7.  Analog computer monitoring and evaluation of a dosing nomogram for gentamicin based on the c'min-method: Part I.

Authors:  W A Ritschel; M Banarer; D Diaz; J B Margary; J D Otero
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1980-10

8.  Pharmacokinetics of cefoxitin in patients with normal or impaired renal function.

Authors:  M J Garcia; A Dominguez-Gil; J M Tabernero; J A Sanchez Tomero
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

Review 9.  Pathophysiological and disease-induced changes in drug distribution volume: pharmacokinetic implications.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

10.  Determining aminoglycoside dosage and blood levels using a programmable calculator.

Authors:  P K Ng
Journal:  Am J Hosp Pharm       Date:  1980-02
View more
  6 in total

1.  Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues.

Authors:  M Frossard; C Joukhadar; B M Erovic; P Dittrich; P E Mrass; M Van Houte; H Burgmann; A Georgopoulos; M Müller
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 2.  A reappraisal of current dosing strategies for intravenous fosfomycin in children and neonates.

Authors:  Friederike Traunmüller; Martin Popovic; Karl-Heinz Konz; Patrick Vavken; Andreas Leithner; Christian Joukhadar
Journal:  Clin Pharmacokinet       Date:  2011-08       Impact factor: 6.447

3.  Pharmacokinetics of phosphomycin during haemofiltration.

Authors:  C Fernandez Lastra; E L Mariño; A Dominguez-Gil; J M Tabernero; J Grande Villoria
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

4.  Disposition of phosphomycin in patients with pleural effusion.

Authors:  C F Lastra; E L Mariño; M Barrueco; M S Gervós; A D Gil
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

Review 5.  Fosfomycin: Pharmacological, Clinical and Future Perspectives.

Authors:  Anneke Corinne Dijkmans; Natalia Veneranda Ortiz Zacarías; Jacobus Burggraaf; Johan Willem Mouton; Erik Bert Wilms; Cees van Nieuwkoop; Daniel Johannes Touw; Jasper Stevens; Ingrid Maria Catharina Kamerling
Journal:  Antibiotics (Basel)       Date:  2017-10-31

6.  Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection.

Authors:  Sander G Kuiper; Anneke C Dijkmans; Erik B Wilms; Ingrid M C Kamerling; Jacobus Burggraaf; Jasper Stevens; Cees van Nieuwkoop
Journal:  J Antimicrob Chemother       Date:  2020-11-01       Impact factor: 5.758

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.